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Five-Year Survival After Liver Transplantation 
S. Iwatsuki, B.W. Shaw, Jr, and T.E. Starzl 
THROUGH 1979, immunosuppressive therapy for liver transplantation at our 
center was with azathioprine (or cyclophos-
phamide) and steroids, to which antilympho-
cyte gloublin (ALG) was usually added. 1- 3 
Failure was more frequent than success. Nev-
ertheless, 55 (32.4%) of the first 170 recip-
ients treated from 1963 on in Denver survived 
for more than a year, and 31 (18.2%) passed 
or are just reaching the five-year mark. The 
following is an account of these pioneer 
patients who have become the leaders in a 
population of liver recipients that will be 
expanding rapidly with the improved immu-
nosuppression that is available today. 
CASE MATERIAL 
The 170"llatients were treated with orthotopic liver 
transplantation at the University of Colorado Health 
Sciences Center from March I, 1963, through the first 
month of 1980. 1-4 Eighty-six of the 170 patients were 18 
years old or younger, and 84 were 19 years or older. All of 
these patients were treated with azathioprine and predni-
sone and most had ALG as well. Sixteen patients (OT 42 
through 57) received cyclophosphamide instead of aza-
thioprine for several months, and 21 were treated with 
thoracic duct drainage as an adjunct to therapy with 
azathioprine and prednisone. 
Cyclosporine was not available for any of these patients 
at the time of transplantation, but in five patients (OT 56, 
77, 137, 142, 164), cyclosporine was substituted for 
azathioprine four to 11 years after the transplant because 
of chronic rejection in four patients and in order to reduce 
the maintenance dose of prednisone for growth retarda-
tion in one patient (OT 142). Two patients (OT 56 and 
137) received second transplants with cyclosporine and 
low-dose steroid therapy, and one patient (OT 164) 
returned to azathioprine after several months of cyclospo-
rine therapy. 
Patient code number (OT number), age at the time of 
transplant, sex, diagnosis of liver disease, survival, present 
status of recipient, cause of death after five years, and 
current immunosuppression therapy are listed in Table I. 
RESULTS 
Survival 
Of the 170 patients, 31 lived for more than 
five years and two others are living and well 
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with normal liver function between 43j4 and 
five years after liver transplantation as of the 
end of August 1984. The latter two patients 
are considered five-year surviv{)fs. The actu-
arial survival rate at five years is 19.4%, and 
that at ten years is 17.9% (Fig 1). 
Of the 33 five-year survivors, 19 were 
among 86 patients between ten months and 18 
years of age and 14 were among 84 patients 
older than 18 years at the time of transplanta-
tion. Thus, five-year survival was better in the 
pediatric age group (22.1 %) than in the adult 
age group (16.7%). 
The influence of preexisting hepatic disease 
upon five-year survival was examined and the 
results are summarized in Tables 2 and 3. In 
the pediatric age group, biliary atresia was the 
most common indication for liver transplanta-
tion; only seven (13.7%) of 51 children with 
this diagnosis survived for more than five 
years (Table 2). In contrast, seven (53.8% of 
13 children with inborn metabolic diseases, 
such as Wilson's disease and alpha-I-anti-
trypsin deficiency disease, lived for five or 
more years as well as three (23.1 %) of 13 
children with chronic aggressive hepatitis and 
cirrhosis. 
In the adult age group, seven (21.2%) of 33 
patients with chronic aggressive hepatitis and 
cirrhosis and three (20%) of 15 patients with 
alcoholic cirrhosis lived more than five years 
after transplantation, which was slightly bet-
ter than the 16.7% overall 5-year survival rate 
among 84 adult patients (Table 3). 
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1 2 3 4 5 6 7 8 9 10 
YEARS AFTER TRANSPLANT 
Fig 1. The survival curve of 170 patients who had 
received orthotopic liver transplantation with azathio-
prine. prednisone. and ALG between 1963 and 1980. 
A total of 23 patients (eight in the pediatric 
and 15 in the adult age groups) had primary 
liver malignancy at the time of transplanta-
tion. Five of the tumors were incidental to 
another disease and were not the principal 
indications for transplantation (Table 2t). 
Two of the five patients (OT 33 and 147) with 
incidental primary liver malignancies are liv-
ing 142/ 3 and 61/ 2 years after transplantation; 
both are free of malignancy (Table 1). Only 
one (5.5%) of 18 patients in whom malignant 
tumors were the principal indication for trans-
plantation lived for more than five years. This 
exceptional patient (OT 114) has no evidence 
Table 2. Main Indications for Liver Transplantation 
and Five-Year Survival in Pediatric Patients 
(Age, ,",,18 Years) 
Type of 
Indication No. of Patients 5-yr Survivors 
Biliary atresia 51 7 (13.7%) 
Inborn metabolic errors· 13 7 (53.8%) 
Chronic aggressive hepatitis 13 3 (23.1%) 
Primary liver malignancyt 3 0 
Neonatal hepatitis 2 0 
Congenital hepatic fibrosis 2 1 (50.0%) 
Secondary biliary cirrhosis:j: 2 1 (50.0%) 
Total 86 19(22.1%) 
"Alpha-1-antitrypsin deficiency disease. nine; Wilson's 
disease. two; tyrosinemia, one; and type IV glycogen storage 
disease, one. 
tFive other patients had incidental malignancies (four 
hepatomas and one hepatoblastoma) in their excised livers. 
The principal diagnosis in these five cases was biliary atresia 
(three), alpha-1-antitrypsin deficiency (one). and congenital 
tyrosinemia (one). 
:j:Secondary to trauma or choledochal cyst (one each). 
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Table 3. Main Indications for Liver Transplantation and 
Five-Year Survival in Adult Patients (Age, ;,,:19 Years) 
Type of 
Indication 
Chronic aggressive hepatitis 
Alcoholic cirrhosis 
Primary liver malignancy' 
Sclerosing cholangitis 
Primary biliary cirrhosis 
Alpha-1-antitrypsin deficiency 
Secondary biliary cirrhosist 
Hemochromatosis 
Protoporphyria 
Budd-Chiari syndrome 
Acute hepatitis B 
Total 
No. of 
Patients 5-yr Survivors 
33 
15 
15 
7 
6 
2 
2 
84 
7 (21.2%) 
3 (20.0%) 
1 (6.7%) 
o 
1 (16.7%) 
o 
1 (50.0%) 
o 
o 
1 (100.0%) 
o 
14 (16.7%) 
"Hepatoma, seven; duct cell carcinoma (Klatskinl. five; 
cholangiocarcinoma, one; hemangioendothelial sarcoma, one; 
and unclassified sarcoma, one. 
tOne example each of possible duct hypoplasia and 
choledochal cyst. Both patients had had multiple operations. 
of tumor recurrence nearly nine years after 
transplantation (Table 1). 
Only three patients were known to be posi-
tive for HBsAg prior to transplantation and 
three more patients became positive after 
transplantation. None of the three patients 
who had positive HBsAg prior to transplanta-
tion lived five years, but all three patients (OT 
77, 115, and 137) who became positive for 
HBsAg after transplantation lived five years 
or longer. Because HBsAg antigen detection 
was not as accurate years ago as it is now and 
was not performed regularly after transplan-
tation, the true incidence and influence of 
HBsAg on survival could not be determined in 
this study. 
Causes of Death After Five Years 
Only two patients died after five years. A 
boy who was 11 years old at the time of 
transplantation (OT 27), died a few days 
before the six-year mark, of chronic liver 
failure. The cause of this liver failure was 
uncertain because the patient had undergone 
several reoperations for biliary duct strictures; 
these could not be completely corrected. In 
addition, medical attention for this patient 
was not sought at his local hospital until he 
became critically ill. Autopsy was not 
5-YEAR SURVIVAL POST-LIVER TRANSPLANT 
granted. It was speculated at that time that he 
might not have had adequate medication, if 
any, for several months prior to his death. 
During his survival period, he obtained a 
junior high school education and he had been 
looking for work (Table 1). 
Another patient (OT 137) died after 
exactly six years. She developed chronic rejec-
tion five years after transplantation. Azathio-
prine was discontinued and cyclosporine ther-
apy was begun. Despite a favorable response 
to this change, the graft function continued to 
deteriorate. She died from necrotizing pan-
creatitis and abdominal sepsis 15 days after 
retransplantation. She had finished high 
school and was married before her death 
(Table 1). 
Rehabilitation: Quality of Life 
Nine children who were below school age at 
the time of transplantation are all attending 
school, one (OT 33) being a college student. 
Of ten children who were in school before 
transplantation, seven graduated, and the 
other three are continuing their education. Of 
the seven who graduated, all worked except 
the one who died (OT 27). Two of them 
married. 
Among the 14 adult patients, 12 are work-
ing full-time including nine housewives. Of 
the nine housewives, four also held full-time or 
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partime jobs outside of the home. One woman 
gave birth twice to healthy babies and another 
woman also has had a normal baby. Two men 
could not keep their regular occupations 
because of both social and medical reasons 
(Table 1). Thus, all but two of the 33 five-year 
survivors were rehabilitated. The quality of 
life has been satisfactory. 
CONCLUSION 
Although these results are far inferior to 
those obtained in recent years with cyclospo-
rine and low-dose steroid therapy, each of 
these 170 heroes or heroines contributed to the 
mass of scientific data and to the development 
of the surgical techniques that have become 
routine today. Even now, their contributions 
continue, and demonstrate that survival 
between five and ten years is more than 90%, 
and that rehabilitation and quality of life are 
excellent, allowing important community ser-
vice, parenthood, and other noble human 
functions. 
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